Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials

Core Insights - Eli Lilly announced that its oral drug, orforglipron, demonstrated effectiveness in reducing blood sugar levels in two late-stage clinical trials [1] Company Summary - Eli Lilly's orforglipron is positioned as a significant advancement in diabetes treatment, showing promising results in clinical trials [1] Industry Summary - The development of orforglipron reflects ongoing innovation in the diabetes medication market, highlighting the competitive landscape among pharmaceutical companies [1]